Cargando…
Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A
The chemoprotective properties of sulforaphane (SF), derived from cruciferous vegetables, are widely acknowledged to arise from its potent induction of xenobiotic-metabolizing and antioxidant enzymes. However, much less is known about the impact of SF on the efficacy of cancer therapy through the mo...
Autores principales: | Erzinger, Melanie M., Bovet, Cédric, Hecht, Katrin M., Senger, Sabine, Winiker, Pascale, Sobotzki, Nadine, Cristea, Simona, Beerenwinkel, Niko, Shay, Jerry W., Marra, Giancarlo, Wollscheid, Bernd, Sturla, Shana J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780774/ https://www.ncbi.nlm.nih.gov/pubmed/26950072 http://dx.doi.org/10.1371/journal.pone.0150219 |
Ejemplares similares
-
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
por: McKeage, Mark J, et al.
Publicado: (2011) -
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
por: McKeage, Mark J, et al.
Publicado: (2012) -
DNA Adduct Profiles
Predict in Vitro Cell Viability
after Treatment with the Experimental Anticancer Prodrug PR104A
por: Stornetta, Alessia, et al.
Publicado: (2017) -
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3
por: Abbattista, Maria R., et al.
Publicado: (2021) -
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)